Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 11/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22042948 | 0.86 | CYP1A2 (0.67) | PDE9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL22071806 | 0.86 | LMNA (0.59) | PDE9AALDH1A1TSHRESR1 | |
| SCHEMBL22042838 | 0.80 | SMN1; SMN2 (0.52) | PDE9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL19342087 | 0.79 | DAPK3 (0.61) | PDE9AMEN1KMT2ACYP1A2CYP3A4 | |
| SCHEMBL22042828 | 0.79 | SMN1; SMN2 (0.52) | PDE9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL22042836 | 0.78 | ALDH1A1 (0.50) | PDE9AMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL22042856 | 0.78 | TSHR (0.74) | MEN1KMT2AALDH1A1HPGDCYP1A2 | |
| SCHEMBL19342102 | 0.77 | MEN1 (0.69) | PDE9AMEN1KMT2AALDH1A1CYP1A2 | |
| SCHEMBL22042911 | 0.75 | PDE9A (0.57) | PDE9A | |
| SCHEMBL22042840 | 0.75 | KMT2A (0.77) | MEN1KMT2AALDH1A1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-07 | — | — | US | disclosed |
| EP-3892622-B1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RES INST CHEMICAL TECH (KR) | 2024-07-24 | — | — | EP | disclosed |
| CN-113166159-B | Compounds having PDE9A inhibiting activity and pharmaceutical uses thereof | 韩国化学研究院 | 2023-10-24 | — | — | CN | disclosed |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2022-01-20 | — | — | US | disclosed |
| EP-3892622-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| EP-3892622-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | Korea Research Institute of Chemical Technology (KR) | 2021-10-13 | — | — | EP | disclosed |
| CN-113166159-A | Compound with PDE9A inhibitory activity and pharmaceutical use thereof | 韩国化学研究院 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
| WO-2020116972-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | 한국화학연구원 | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | PDE9A 1/4885MEN1 2770/4885KMT2A 1360/4885 |
| US-20220017528-A1 | COMPOUNDS HAVING PDE9A INHIBITORY ACTIVITY, AND PHARMACEUTICAL USES THEREOF | PDE9A, PDE5A, PDE3A | PDE9A 1/4885MEN1 2770/4885KMT2A 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.